RxDoctor Payments DataLook up a doctor →

Chirag Shah

Gynecologic Oncology · Seattle, WANPI 1235248360

Payments from drug & device makers

$731,981in general payments, 2019–2025

Across 668 payments — averaging $1095.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$234K
  • AbbVie$121K
  • Genmab U.S., Inc.$96K
  • Tesaro, Inc.$77K
  • Seagen Inc.$46K
  • Clovis Oncology, Inc.$40K
  • plus $117K from 15 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$731,981 in reported general payments places this provider in the 80th percentile of 36 gynecologic oncology providers in Washington.

See all gynecologic oncology providers in Washington

Medicare billing

Part B allowed, 2024
$122,552
Medicare patients
125
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →